Startups

TREATMiNT offers monthly gift box for cancer patients

Kimberly Fink started the company after her own battle with cancer.

Kimberly Fink was 32 when she was diagnosed with uterine cancer.

After surgery, radiation and chemotherapy, Fink went into remission and had a new goal: to improve the experience of other cancer patients. That’s the idea behind TREATMiNT Box, a monthly subscription box full of gifts for cancer patients, survivors and caregivers.

Fink, now 35, of East Falls, said she created TREATMiNT because she noticed that people felt like they didn’t know how to support loved ones battling cancer.

The boxes, which start at $50 for one month and get cheaper if you buy a longer subscription, include products like hand cream and an art print with an inspirational quote in it.

Fink recently spoke about TREATMiNT at coworking space Walnut St. Labs.

//

 

The revenue model, Fink said, is three-fold:

  • The subscription boxes,
  • individual products (including wholesale, which has not launched yet) and
  • co-branding boxes for hospitals, nonprofits and other organizations.

Fink declined to disclose revenue numbers. She’s the only one working full-time on the project and is currently raising a round of funding. She’ll also be heading to tech conference Web Summit Dublin as part of its “Alpha” startup program next month.

The product has gotten early buzz from Philadelphia Magazine, landing a spot on its “Best of Philly” list.

Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Donate to the Journalism Fund

Your support powers our independent journalism. Unlike most business-media outlets, we don’t have a paywall. Instead, we count on your personal and organizational contributions.

Trending

PTW 2025 live blog: A sneak peek at next year’s events

The case for storytelling: Want your region’s tech scene to grow? Start with a story, new data says

Why every city has a ‘startup week’ now — and whether they should

Spark layoffs won’t derail Philadelphia’s biotech surge, city official says

Technically Media